Supplement references:

  1. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-75. doi: 10.1001/jama.2011.90.
  2. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303-10. doi: 10.1016/S1470-2045(14)70460-7. Epub 2014 Oct 15.
  3. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32:1507-15. doi: 10.1200/JCO.2013.53.3935. Epub 2014 Feb 10.
  4. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455-61. doi: 10.1001/jama.2013.278932.
  5. Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609-18. doi: 10.1016/S1470-2045(13)70166-9. Epub 2013 May 15.
  6. Benson JR, Jatoi I. Sentinel lymph node biopsy and neoadjuvant chemotherapy in breast cancer patients. Future Oncol. 2014;10:577-86. doi: 10.2217/fon.13.231. Review.
  7. Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, et al. Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer. Ann Surg Oncol. 2015 Aug 15. [Epub ahead of print]
  8. Stoffels I, Dissemond J, Pöppel T, Schadendorf D, Klode J. Intraoperative Fluorescence Imaging for Sentinel Lymph Node Detection: Prospective Clinical Trial to Compare the Usefulness of Indocyanine Green vs Technetium Tc 99m for Identification of Sentinel Lymph Nodes. JAMA Surg. 2015;150:617-23. doi: 10.1001/jamasurg.2014.3502.
  9. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11.
  10. Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst. 2013;105:1504-11. doi: 10.1093/jnci/djt244. Epub 2013 Sep 12.
  11. Drukker CA, van Tinteren H, Schmidt MK, Rutgers EJ, Bernards R, van de Vijver MJ, Van't Veer LJ. Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat. 2014;143:587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21.
  12. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14:1067-76. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12.
  13. Nielsen T, Wallden B, Schaper C, Ferree S, Liu S, Gao D,et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014;14:177. doi: 10.1186/1471-2407-14-177.
  14. Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics. 2015;8:54. doi: 10.1186/s12920-015-0129-6.
  15. Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, et al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol. 2015;26:1685-91. doi: 10.1093/annonc/mdv215. Epub 2015 May 1.
  16. Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, et al. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015107. pii: djv179. doi: 10.1093/jnci/djv179. Print 2015 Sep.
  17. Martin M, Brase JC, Calvo L, Krappmann K, Ruiz-Borrego M, Fisch K, et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res. 2014;16:R38. doi: 10.1186/bcr3642.
  18. Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P,et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 2015;33:916-22. doi: 10.1200/JCO.2014.55.6894. Epub 2014 Oct 20.
  19. Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014;25:339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.
  20. Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013;24:640-7. doi: 10.1093/annonc/mds334. Epub 2012 Oct 3.
  21. Masuda S. Pathological examination of breast cancer biomarkers: current status in Japan. Breast Cancer. 2014. [Epub ahead of print]
  22. Barton S, Zabaglo L, A'Hern R, Turner N, Ferguson T, O'Neill S, et al. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer. 2012;106:1760-5. doi: 10.1038/bjc.2012.166. Epub 2012 Apr 24.
  23. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273-8. doi: 10.1200/JCO.2010.31.2835. Epub 2011 Oct 11.
  24. Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Fu P, Honda Y, et al. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki67 and the corresponding gene expression score in breast cancer. Mod Pathol. 2013;26:79-86. doi: 10.1038/modpathol.2012.151. Epub 2012 Aug 24.
  25. Onoda T, Yamauchi H, Yagata H, Tsugawa K, Hayashi N, Yoshida A, et al. The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients. Breast Cancer 2015, 22: 406-12.